ArticleCancer medicine2021
Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Tyrosine kinase inhibitors in Ewing's sarcoma: a systematic review.BMC cancer · 2025Pooled it
- Efficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity.Science advances · 2026Trial
- All-site radiotherapy for metastatic ewing's sarcoma: a short-term analysis of feasibility, response, and safety.Clinical & experimental metastasis · 2026Article
- Multi-Targeted TKIs in Patients with Advanced Ewing Sarcoma: A Systematic Review and Single-Arm Meta-Analysis.Cancers · 2026Review
- Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.Frontiers in oncology · 2026Article
- Case Report: Anlotinib for advanced chordoma.Frontiers in oncology · 2026Article
- Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.Pharmacological reports : PR · 2025Review
- NClinical and translational medicine · 2025Article
- Safety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study.Anti-cancer agents in medicinal chemistry · 2025Article
- Primary hepatic epithelioid hemangioendothelioma: a case report.The Journal of international medical research · 2024Article
- Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma.Current treatment options in oncology · 2024Review
- Review
- Cadonilimab plus anlotinib effectively relieve rare cardiac angiosarcoma with multiple metastases: a case report and literature review.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Review
- Recurrent retroperitoneal liposarcoma with multiple surgeries: a case report.Frontiers in oncology · 2024Article
- Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.Frontiers in immunology · 2024Article
- The function and mechanism of PSMD14 in promoting progression and resistance to anlotinib in osteosarcoma.Cancer cell international · 2023Article
- Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.Journal of bone oncology · 2023Review
- Case report of severe pneumothorax due to lung cancer treated with anlotinib.The Journal of international medical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib have demonstrated encouraging activity in prolonging progression-free survival (PFS) in several bone sarcoma entities in prospective clinical trials. This retrospective study aims to analyze the safety and efficacy of anlotinib, a novel multi-target TKI, in patients with locally unresectable or metastatic bone sarcoma at three institutions.
methodsPatients with advanced bone sarcoma administered anlotinib 12 mg once daily, 2 weeks on/1 week off, from June 2018 to June 2020, until disease progression or intolerance of treatment. The primary endpoints were objective response rate (ORR) and PFS.
resultsForty-eight patients were analyzed: 27 have osteosarcoma, 9 have chondrosarcoma, 8 have Ewing's sarcoma, and 3 have chordoma. The median age was 24 years (range, 16-68 years), and the median number of prior regimens was 1 (range, 0-4). Until the final follow-up, five patients obtained a partial response and while 24 achieved stable disease. The ORR in all patients was 10.4%, and the median PFS was 4.6 months, with a progression-free rate (PFR) at 3 months and 6 months of 72.9% and 35.4%, respectively. The ORR and median PFS varied much among tumor subtypes. The most frequent grade 3-4 adverse events (AEs) were pneumothorax, hand-foot syndrome, cholesterol elevation, hypertriglyceridemia, and fatigue. No patients died from anlotinib-related AEs during the study period.
conclusionsAnlotinib may show promising antitumor activity in unresectable or metastatic bone sarcoma. The ORR and median PFS of anlotnib are similar to those of other targeted drugs in different subtypes of sarcomas. The AEs were generally mild and tolerated well. Further studies of anlotinib in selected subtypes of bone sarcoma are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.